Atai Life Sciences N.V. (NASDAQ:ATAI) saw an upside of 1.59% to $1.92 after adding $0.03 on Tuesday. The 5-day average trading volume is 1,439,754 shares of the company’s common stock. It has gained $2.0350 in the past week and touched a new high 2 times within the past 5 days. An average of 2,071,543 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,561,147.
ATAI’s 1-month performance is -36.58% or -$0.7500 on its low of $1.4500 reached on 01/06/23. The company’s shares have touched a 52-week low of $1.45 and high of $6.32, with the stock’s rally to the 52-week high happening on 01/04/23. YTD, ATAI has lost -28.95% or -$0.7400 and has reached a new high 2 times. However, the current price is down -69.62% from the 52-week high price.
Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 804.48 while the price-to-book (PB) in the most recent quarter is 1.02.
Atai Life Sciences N.V.’s quick ratio for the period ended September 29 was 12.30, with the current ratio over the same period at 12.30. The firm’s gross profit as reported stood at $156.18 million against revenue of $20.38 million.
For the quarterly period ending September 29 this year, Atai Life Sciences N.V.’s cash and short-term investments amounted to $161.52 million against total debt of $17.1 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 8.06% to -$33.89 million, while revenue of -$36.62 million was -8.06% off the previous quarter. Analysts expected ATAI to announce -$0.23 per share in earnings in its latest quarter, but it posted -$0.22, representing a 4.30% surprise. EBITDA for the quarter stood at more than -$38.39 million. ATAI stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 46.52 million, with total debt at $17.1 million. Shareholders hold equity totaling $165.88 million.
Let’s look briefly at Atai Life Sciences N.V. (ATAI) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 38.30% to suggest the stock is trending Neutral, with historical volatility in this time period at 57.83%.
The stock’s 5-day moving average is $1.9340, reflecting a -1.03% or -$0.0200 change from its current price. ATAI is currently trading -36.84% above its 20-day SMA, -55.14% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -29.41% and SMA200 by-60.98%.
Stochastic %K and %D was 34.74% and 36.27% and the average true range (ATR) pointed at 0.1838. The RSI (14) points at 37.26%, while the 14-day stochastic is at 36.02% with the period’s ATR at 0.2057. The stock’s 9-day MACD Oscillator is pointing at 0.0189 and -0.0617 on the 14-day charts.
In the most recent analyst report for Atai Life Sciences N.V. (NASDAQ: ATAI), Loop Capital launched coverage with a Buy rating. Analysts offering their rating for ATAI stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ATAI as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 13 have offered a “buy” rating.
What is ATAI’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $5.10 and a high of $21.00, with their median price target at $11.00. Looking at these predictions, the average price target given by analysts is for Atai Life Sciences N.V. (ATAI) stock is $12.66.